pharma · Moderate to severe pain associated with Osteoarthritis of the knee · Not applicable for phase I study
Grünenthal
Gruenenthal GmbH
Gruenenthal is a pharma organization headquartered in EU. Primary therapeutic focus areas include Moderate to severe pain associated with Osteoarthritis of the knee, Not applicable for phase I study. NovaPharmaNews links
Aachen, DE HQ
4,668 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Aachen, DE
- Employees
- 4,668
- Programs
- 3
- Drugs
- 5
- Patents
- 0
RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung
Phase 3 · small molecule · Moderate to severe pain associated with Osteoarthritis of the knee
RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung for Moderate to severe pain associated with Osteoarthritis of the knee is a Phase 3 program (small_molecule) at Gruenenthal GmbH with 1 ClinicalTrials.gov record(s).
Internal code KF7039-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Gruenenthal GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Moderate to severe pain associated with Osteoarthritis of the knee
- Status
- active
- Trials
- 1